ORA Reminder: Please note that in the new SoonerTrack system, when a Key Participant on a proposal commits cost-shared effort to the project, only the Financially Responsible Department (FRD) and the Key Participant will be informed of the commitment. The cost-shared effort is listed on the Key Participant’s Compliance Form and is approved by them. Keep in mind that the Key Participant's Business Manager or the Department Approver will not have access to their Compliance Forms or, consequently, their effort commitment. Therefore, it is the Principal Investigator, their FRD, and the Key Participant's responsibility to ensure that the cost-shared effort on the grant is communicated with the Key Participant's department.  

 

Resources Available to Researchers for Preparing NIH Data Management and Sharing Plans

OU IT has provided some resources and guidance on research data storage and costs. Please refer to the documents below that are attached.

• Research Data Infographics (PDF)
• Research Matrix (PDF) 

 

IMPORTANT NOTE: Please be aware that effective for applications submitted for due dates on or after October 5, 2023, NIH will no longer require the use of the single DMS cost line item. NIH recognizes that DMS costs may be requested in many cost categories. Therefore, in line with NIH standard budget instructions, DMS costs must be requested in the appropriate cost category, e.g., personnel, equipment, supplies, and other expenses, following the instructions for the R&R Budget Form or PHS 398 Modular Budget Form, as applicable. While the single cost line item is no longer required for applications submitted for due dates on or after October 5, 2023, NIH will require applicants to specify estimated DMS cost details within the “Budget Justification” attachment of the R&R Budget Form or “Additional Narrative Justification” attachment of the PHS 398 Modular Budget Form, pursuant to the instructions. For more information, please see https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-161.html. For applications submitted before October 5, 2023, you are still required to include the “Data Management and Sharing Costs” line item under F. Other Direct Costs on the R&R Budget Form.

 

Drawing a Blank? Samples Can Get You Started!

If you are new to writing grant applications, sometimes seeing how someone else has presented their idea can help as you are developing your own application. With the gracious permission of successful investigators, some institutes have provided samples of funded R01, R03, R15, R21, SBIR/STTR, K, and F applications, sharing plans, leadership plans, and more. They have even provided sample summary statements so you can know what to expect to receive as the outcome of the review of your application.

 

New and Updated courses now available through Nature Masterclasses

The NEW Effective Science Communication course was developed in collaboration with a team of 8 experts in science communication, science writing and editing, science outreach, engagement and presentations, and the Springer Nature press office.
This course is to help researchers understand how storytelling techniques can build a compelling scientific story to communicate their research and apply strategies in an accessible and persuasive way to a non-scientific audience.

• Compare different audience requirements to help you tailor your communications
• Select a relevant communication channel for your specific needs in a particular instance.
• Tips and techniques for communication your research via writing, public talks and presentations, social media, and media interviews

Also, the Scientific Writing and Publishing and Effective Collaboration in Research courses have new and updated content.
To access the OUHSC Library Institutional Subscription for Nature Masterclasses follow the instructions below to access the link and register to create a login.  A login is required to access the courses and track progress.

• Use this link or go to the library's home page and navigate to More Resources, All databases & Resources A-Z, Select the letter N and scroll down to Nature Masterclasses, Click on the link
• You will need to register while on the campus network (or VPN) to create a login. Ignore language to request a quote or buy a subscription, and register using the button in the top right-hand corner.  This language may still appear after you log in.
• Once registered you can use your login from anywhere. 
• NOTE:  While on the campus network (or VPN) you will have to login to NMC approximately every 6 months to verify that you are a valid user.  You must have valid OUHSC credentials to continue to use NMC.

 

Moving to OUHSC with Your Grants: An Overview of the Grant Transfer Process

Description: Are you a new faculty researcher who has recently transferred from another institution to OUHSC and have an active or pending grant? If so, this presentation is for you!
In this session, the Office of Research Administration (ORA) will provide the new incoming researchers with a better understanding of the grants transfer process at HSC, as well as the required trainings and procedures. We will also provide an overview of the ORA proposal routing and submission processes.
New researchers and department administrators who want to familiarize themselves with the ORA grant submission processes are welcome to join too!
When: Wednesday, September 13, 2023 2:00 PM-3:00 PM
Location: Zoom. Please register in advance: https://ousurvey.qualtrics.com/jfe/form/SV_2awZLJ9DaROKoIK

 

OK NSF EPSCoR Professional Development Seminar Series

Description: Join us as we discuss new NSF EPSCoR funding opportunities, and dive into the highlights of E-RISE. Our 2023 seminar series is continuing Wednesday, Sept. 6, from noon to 1:00 p.m. (Central Time); see below for log-in details. The meeting, "EPCSoR Research Incubators for STEM Excellence Research Infrastructure Improvement (E-RISE RII)," will be presented by JD Swanson, Program Director of the Office of Integrative Activities within NSF. Detailed meeting log-in information can be found below.
The OK NSF EPSCoR Professional Development Seminar Series is designed to enhance researchers' professional growth by addressing a broad range of timely and relevant topics, including diversity, mentorship, developing new PIs, interdisciplinary and team science, and more. The quarterly meeting series supports researchers at all career levels, from students to endowed faculty; institutions across the state are encouraged to participate.
Time: September 6, 2023, 12:00 PM Central Time (US and Canada)
Join Zoom Meeting: https://us02web.zoom.us/j/81947444226?pwd=ZW9CaXIyWVJqcFV2TVROcEZWSWNkZz09
Meeting ID: 819 4744 4226
Passcode: epscor
QUESTIONS: Email Kaley Barnicoat, Outreach Coordinator, at kbarnicoat@okepscor.org or call 405.744.9964.

 

American Cancer Society Institutional Research Grant (ACS-IRG) – Fall 2023 Cycle

Description: The ACS-IRG is a unique source of funding entrusted to Stephenson Cancer Center (SCC) that provides seed money for early-stage faculty interested in cancer-related research - the ACS has provided SCC with supplemental monies that allow support up to two awards.  ACS-IRG funds will provide $60,000 to new/early stage faculty with Cancer Research pilot projects.
Eligibility Criteria:

• ASSISTANT PROFESSOR or equivalent level position that holds a Tenure- or Research-track appointment on OUHSC, OU-Norman or OU-Tulsa campus and within SIX years of first independent academic appointment.
• Without CURRENT grant support from national funding agencies (e.g. NIH, DOD, NSF, ACS).

LOI Deadline: Wednesday, September 20^th, 2023, Due by 5:00 PM (CST)
Full Application Deadline: Tuesday, October 31^st, 2023, Due by 5:00 PM (CST)
Application, Guidelines and more information can be found:  SCC Website | ACS IRG Guidelines
Questions: If you miss the LOI deadline and would like to submit or have any other questions, please contact The SCC Office of Cancer Research at SCC-InternalGrants@ouhsc.edu.  

 

2023 OSCTR Pilot Grants Program

Description: The Oklahoma Clinical and Translational Science Institute (OCTSI) and Oklahoma Shared Clinical and Translational Resources (OSCTR) is soliciting applications for its Clinical and Translational Research Pilot (CTRP) Grants Program. The purpose of the program is to provide funding for clinical and translational pilot projects from investigators of the OSCTR member institutions and preference is given to investigators who qualify as NIH New or Early Stage Investigators, or to investigators who are transitioning to clinical and translational research. The program seeks to support proposals designed to generate preliminary data that will result in improved health and/or health outcomes for citizens of Oklahoma and other IDeA states and enhance the competitiveness of the investigator for future extramural funding. The program also seeks to fund innovative concepts, approaches, and methodologies that bring fresh new ideas to solving the health issues of those living in Oklahoma and collaborating IDeA states. Projects that focus on the medically underserved and on health concerns prevalent within Oklahoma and our OSCTR partners will be a priority. Only projects which meet the NIH definition of clinical and/or translational research will be accepted.
The forms, instructions, and submission link can be found at:  http://osctr.ouhsc.edu/pilots2023. Deadline: Friday, September 15, 2023 at 5:00 PM CDT. If you have any technical questions about the grant submission process or grant eligibility please contact the OSCTR Research Navigator Service at osctr@ouhsc.edu or call 405-271-3480.

 

Investigator Initiated Trials Funding Committee (IITFC), Clinical Trials Office-Protocol Support Unit

Description: Grant proposals are being accepted for the 2023 Fall cycle from Stephenson Cancer Center Providers for their investigator-initiated clinical trials (IITs) or translational work for the amount of up to $100,000 for clinical trials, and up to $25,000 for translation research. All applications should be submitted to the Protocol Support Unit at SCC-IIT-Office@ouhsc.edu and should adhere to the Grant template and Submission Checklist provided with this notice. Investigators should request the budget template from the CTO Budget Manager (ClinicalTrialBudgets@ouhsc.edu). 
Deadline: October 9^th, 2023 at 5 pm CST
Link to the full announcement or a flier: Please refer to the attached flyer for additional funding criteria and details.

 

Once-a-year NIH SBIR Contract Solicitation from NIH (PHS-2024-1)

Any OUHSC researcher interested in commercializing their research should look at this once-a-year solicitation.  It relates to one of the following specific areas listed below. The once-a-year NIH SBIR Contract Solicitation will soon be coming out and from prior experience of other investigators it is often the single easiest SBIR award mechanism to get a fundable score. This is not the normal, more academic NIH SBIR, the contract proposals don’t go through the Center for Scientific Review (CSR).  The awards directly fund what NIH program managers want to fund. So if, you are interested in launching a startup, securing SBIR funding, and there is a topic in the list below that matches your area of interest, this could be a great opportunity. If any faculty are interested they can contact John Hanak (jhanak@ou.edu), the Chief Innovation and Corporate officer that oversees these activities on the OUHSC, OU-Norman, and OU-Tulsa campuses. He will be able to get you in touch with the OK Catalyst team and they will help you through the process.  

THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2024-1
NATIONAL INSTITUTES OF HEALTH (NIH)
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS):
Topic 024 - Small Manufacturing Systems to Produce Research Grade Pharmaceutical Intermediates
NATIONAL CANCER INSTITUTE (NCI):
Topic 455 - Point-of-Care Detection of Prostate Specific Antigen
Topic 456 - Rapid and Affordable Point-of-Care HPV Diagnostics for Cervical Cancer Control
Topic 457 - Technologies for Detecting Tumor-Derived Cell Clusters
Topic 458 - Microbiome-Based Tests for Cancer Research, Diagnosis, Prognosis and/or Patient Management
Topic 459 - Automated Software for Point-of-Care Testing to Identify Cancer-Associated Malnutrition
Topic 460 - Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies
Topic 461 - Ultra-Fast Dose Rate (FLASH) Radiation Detectors and Safety Systems for Cancer Treatment
Topic 462 - Organ-on-Chip for Preclinical and Translational Radiobiological Studies
Topic 463 - Translation of Novel Cancer-specific Imaging Agents and Techniques to Mediate Successful Image-guided Cancer Interventions
Topic 464 - Cloud-Based Multimodal Data Analysis Software for the Cancer Research Data Commons
Topic 465 - Cancer Prevention and Treatment Clinical Trials Tools for Recruitment and Retention of Diverse Populations
NATIONAL INSTITUTE ON AGING (NIA): 
Topic 010 - Technology to facilitate characterization of the exosome in under –resourced populations for AD/ADRD Studies
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID):
Topic 124 - Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV-1 Broadly Neutralizing Antibodies
Topic 125 - Development of Long-Acting Treatments for HCV Cure
Topic 126 - Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection
Topic 127 - Multiplexed Patient Administered Diagnostics for Hepatitis B, Hepatitis C, and HIV
Topic 128 - Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases
Topic 129 - Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models
Topic 130 - Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases
Topic 131 - Development of Bacteriophage for Treatment of Mycobacterial Infections
Topic 132 - Novel Diagnostic Biomarker Discovery and Validation for Malaria and Select Neglected Tropical Diseases (NTDs)
Topic 133 - Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections
Topic 134 - Alternatives to Benzathine Penicillin for Treatment of Syphilis
Topic 135 - Software or Web Services to Automate Metadata Enrichment and Standardization for Data on Infectious and Immune – Mediated Diseases
Topic 136 - Software or Web Services to Re-Represent Existing Scientific Data and Knowledge into a Knowledge Graph Format
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI):
Topic 115 - Clinical Instrument for Para-Hydrogen (pH2) Based Signal Amplification by Reversible Exchange (SABRE) for Hyperpolarizing 13C-Pyruvate and Other Probes for MRI Imaging
NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH):
Topic 001 - Point-of-Care HIV Viral Load and Drug Adherence Assays
Topic 002 - Development of novel In-vitro and In-vivo Models to support NeuroHIV Research

 

Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

• A global personal care company is looking for biodegradable molecules with antimicrobial properties for use in cosmetic formulas.  Molecules should target/disrupt bacterial membranes by any modality and ideally have a broad antimicrobial activity.  Solubility in water, ethanol and DMSO acceptable with water preferred and no/low skin penetration.  Submission entails a one-page 200-300 word non-confidential brief.  (deadline 09/08). 
• Novus International is seeking novel opportunities and ideas in inhibition of methanogenesis in ruminants.  Approaches of interest include antibodies and lytic enzymes; research involving either natural or synthetic compounds considered. Submission entails a one-page 200-300 word non-confidential brief.  (deadline 09/22). 

NOTE: If the project is selected to move forward with a full application, it will need to be routed through SoonerTrack II.

 

• Notice of NCIs Participation in RFA-HG-23-041 Network of Genomics-Enabled Learning Health Systems (gLHS) Clinical Sites (U01, Clinical Trial Required)
  (NOT-CA-23-087)
• Notice of Informational Webinar on the NIH Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Program Notices of Funding Opportunity (K99/R00 and UE5)
  (NOT-GM-23-053)
• Request for Information (RFI): Inviting Comments and Suggestions on Updating the NIH Mission Statement
  (NOT-OD-23-163)
• Notice of Change in Eligibility to Part I for RFA-DK-23-001 "A Consortium for Gut-Brain Communication in Parkinsons Disease (U24 Clinical Trial not allowed)"
  (NOT-DK-23-030)
• Notice of Changes of PAR-21-314 "Blueprint MedTech: Incubator Hubs (U54 Clinical Trial Not Allowed)"
  (NOT-EB-23-016)
• Notice of Intent to Publish a Funding Opportunity for The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional)
  (NOT-CA-23-081)
• Notice of Intent to Publish a Funding Opportunity Announcement for Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)
  (NOT-CA-23-084)
• Notice of Intent to Publish a Funding Opportunity Announcement for Pre-Cancer Atlas (PCA) Research Centers (U01 Clinical Trial Not Allowed)
  (NOT-CA-23-085)
• Notice of Intent to Publish a Funding Opportunity Announcement for Human Tumor Atlas (HTA) Research Centers (U01 Clinical Trial Not Allowed)
  (NOT-CA-23-086)
• Notice of Intent to Publish a Funding Opportunity Announcement for Justice Community Overdose Innovation Network - Phase II Research Hubs (U01 Clinical Trial Required)
  (NOT-DA-25-025)
• Notice of Special Interest (NOSI): Epidemiology and Prevention in Alcohol Research
  (NOT-AA-23-018)
• Notice of Special Interest: National Center for Complementary and Integrative Health (NCCIH) T32 Supplement Program to Promote Diversity in Health Research
  (NOT-AT-24-012)
• Notice of Special Interest (NOSI): Promoting implementation research to address HIV-associated comorbidities and risk factors within well-established longitudinal studies (R01 Clinical Trial Optional) (NOT-HL-23-113)

 

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

 

• Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
  (PA-23-263)
  Application Receipt Date(s): September 07, 2025
• AHRQ Improving Diagnostic Safety in Ambulatory Care: Strategies and Interventions (R18)
  (PA-23-290)
  Application Receipt Date(s): August 31, 2028
• AHRQ Understanding and Improving Diagnostic Safety in Ambulatory Care: Incidence and Contributing Factors (R01)
  (PA-23-291)
  Application Receipt Date(s): August 31, 2028
• Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
  (PAR-23-274)
  Application Receipt Date(s): November 19, 2026
• Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
  (PAR-23-279)
  Application Receipt Date(s): January 07, 2027
• Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
  (PAR-23-280)
  Application Receipt Date(s): January 07, 2027
• Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
  (PAR-24-027)
  Application Receipt Date(s): October 30, 2026
• Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed)
  (RFA-AG-24-046)
  Application Receipt Date(s): February 07, 2024
• The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
  (RFA-CA-23-042)
  Application Receipt Date(s): Multiple dates, see announcement.
• HEAL Initiative: Justice Community Overdose Innovation Network (JCOIN) - Phase II Methodology and Advanced Analytics Resource Center (UM1 Clinical Trial Not Allowed)
  (RFA-DA-24-068)
  Application Receipt Date(s): October 30, 2023
• HEAL Initiative: Justice Community Overdose Innovation Network (JCOIN) - Phase II Coordination and Translation Center (U2C Clinical Trial Optional)
  (RFA-DA-24-069)
  Application Receipt Date(s): October 30, 2023
• Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional)
  (RFA-DA-25-018)
  Application Receipt Date(s): Multiple dates, see announcement.
• Community Partnerships to Advance Science for Society (ComPASS): Health Equity Research Hubs (UC2 Clinical Trial Optional)
  (RFA-RM-23-012)
  Application Receipt Date(s): October 31, 2023

 

The National Cancer Institute (NCI): Informatics Technology for Cancer Research (ITCR)

Description: The ITCR program has funding opportunities aimed at successive stages of informatics technology development, including:

• Innovative Algorithm Development,
• Prototyping and Hardening,
• Advanced Development and Enhancement, and
• Sustainment of Tools.

Next receipt date is November 17, 2023.
Contact Dr. Juli Klemm with questions at juli.klemm@nih.gov.

 

The National Cancer Institute (NCI): Innovative Molecular Analysis Technologies (IMAT)

Description: The IMAT program has funding opportunities to support the development of technologies suitable for the molecular and cellular targeting or analysis of cancers and their host environment in support of basic, clinical, and epidemiological research:

• Early-stage innovative molecular and cellular analysis technologies
• Advanced development and validation of emerging technologies

IMAT also supports the development of novel technologies for sample collection, processing, and preservation:

• Early-stage innovative biospecimen science technologies
• Advanced development & validation of biospecimen science technologies

Incorporate new technologies into your ongoing research.
NCI offers supplemental funding for current NCI grantees to incorporate new technologies developed through the IMAT program into their ongoing research. Applications should offer to accelerate the research and may increase the scope of the projects in addition to promoting collaborations and independent validation of these technologies. Check out the list of IMAT projects to find new technologies that could advance your research!
Next receipt date is September 1, 2023.
Contact Dr. Kelly Crotty or Dr. Tony Dickherber with questions at kelly.crotty@nih.gov or anthony.dickherber@nih.gov.

 

NOT-CA-22-083: NCI has issued a Notice of Special Interest to support the development of technologies and informatics tools specifically for metabolomics and lipidomics research in cancer.
NOT-CA-23-037: NCI has issued a Notice of Special Interest to support the development of technologies and informatics tools specifically for research in cancer control and population sciences.

 

Advanced Research Projects Agency for Health (ARPA-H) Open Broad Agency Announcement (BAA)

Description: The mission of ARPA-H is to accelerate better health outcomes for everyone by supporting the development of high-impact solutions to society's most challenging health problems. Awardees will develop groundbreaking new ways to tackle health-related challenges through highpotential, high-impact biomedical and health research. With a scope spanning the molecular to the societal, ARPA-H seeks proposals that aim to rapidly achieve better health outcomes across patient populations, communities, diseases, and health conditions, including in support of the Cancer Moonshot. Proposals are expected to use innovative approaches to enable revolutionary advances in science, technology, or systems.
Abstract deadline: March 14, 2024
Link to Full Announcement: https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view#general

 

Melanoma Research Alliance (MRA) 2023-2024 Request for Proposals

Description: The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, and treatment.
Proposals will be accepted for Team Science Awards, Team Science Academic-Industry Partnership Awards, Young Investigator Awards, Dermatology Career Development Awards (new for 2023-2024), and Pilot Awards. Special opportunities are also available in acral melanoma, melanoma brain metastases, dermatology technologies, immunotherapy, radiation oncology, uveal melanoma, and UK or Israel based researchers. We intend to support at least $11.5 million in new funding through this RFP.
Applications Deadline:

• September 20, 2023: Letters of Intent (LOI) for Team Science Awards due
• October 20, 2023: Eligibility Checklist for Young Investigator & Dermatology Career Development Award applicants due
• November 3, 2023: Proposals for individual investigator awards due
• January 4, 2024: Invited Team Science Award full proposals due

Link to Full Announcement: https://www.curemelanoma.org/research/request-for-proposals/mra-general-rfp